View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Consumer Portfolio Services Inc: 2 directors

Two Directors at Consumer Portfolio Services Inc sold after exercising options/sold 109,369 shares at between 8.494USD and 8.620USD. The significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary tr...

Jonathan Moreland
  • Jonathan Moreland

Monthly Insider Special Screens: September 1, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Consumer Portfolio Services to Present at the 2025 Gateway Conference ...

Consumer Portfolio Services to Present at the 2025 Gateway Conference on September 3rd LAS VEGAS, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Consumer Portfolio Services, Inc. (Nasdaq: CPSS) (“CPS” or the “Company”), a leader in providing indirect automobile financing to consumers, is confirmed to present at the , which is being held September 3–4 at the in San Francisco, CA. CPS’ management team is scheduled to present on Wednesday, September 3rd at 1:30 p.m. Pacific Time (PT). The presentation will be webcast live and available for replay . In addition to the presentation, CPS executives ...

 PRESS RELEASE

Farmers & Merchants Bancorp (FMCB) Authorizes $45 Million Increase to ...

Farmers & Merchants Bancorp (FMCB) Authorizes $45 Million Increase to Share Repurchase Program LODI, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Farmers & Merchants Bancorp (OTCQX: FMCB) (the “Company” or “FMCB”), the parent company of Farmers & Merchants Bank of Central California (the “Bank” or “F&M Bank”), announced that, effective immediately, the Company has authorized an increase of $45.0 million to the existing share repurchase program along with an extension of the program through December 31, 2027. The increase will bring the total of the share repurchase program to $57.6 million. ...

 PRESS RELEASE

Farmers & Merchants Bancorp (FMCB) Announces Quarterly Cash Dividend

Farmers & Merchants Bancorp (FMCB) Announces Quarterly Cash Dividend LODI, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Farmers & Merchants Bancorp (OTCQX: FMCB) (the “Company” or “FMCB”), the parent company of Farmers & Merchants Bank of Central California (the “Bank” or “F&M Bank”), announced today that the Company is changing its dividend policy related to the frequency of cash dividend payments from semi-annually to quarterly. The unanimous decision to change the frequency of the cash dividend was done after the Board of Directors completed a thorough analysis of the Company’s overall fi...

 PRESS RELEASE

CPS Announces Second Quarter 2025 Earnings

CPS Announces Second Quarter 2025 Earnings Revenues of $109.8 million compared to $95.9 million in the prior year periodPretax income of $7.0 million compared to $6.7 million in the prior year periodRecord high shareholder’s equity- first time over $300 millionNew contract purchases of $433.0 million in the quarter LAS VEGAS, NV, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Consumer Portfolio Services, Inc. (Nasdaq: CPSS) (“CPS” or the “Company”) today announced earnings of $4.8 million, or $0.20 per diluted share, for its second quarter ended June 30, 2025. This represents an increase compared to ...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: August 9, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Opko Health Inc: 1 director

A director at Opko Health Inc bought 675,000 shares at 1.320USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...

 PRESS RELEASE

CPS to Host Conference Call on Second Quarter 2025 Earnings

CPS to Host Conference Call on Second Quarter 2025 Earnings Las Vegas, Nevada, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Consumer Portfolio Services, Inc. (Nasdaq: CPSS) (“CPS” or the “Company”) today announced that it will hold a conference call on Tuesday, August 12, 2025 at 1:00 p.m. ET to discuss its second quarter 2025 operating results. Those wishing to participate can pre-register for the conference call at the following link . Registered participants will receive an email containing conference call details for dial-in options. To avoid delays, we encourage participants to dial into the c...

 PRESS RELEASE

OPKO Health Reports Second Quarter 2025 Business Highlights and Financ...

OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results Conference call begins at 4:30 p.m. Eastern time today MIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and six months ended June 30, 2025. Highlights from the second quarter of 2025 and recent weeks include the following: Merck advanced Phase 1 Epstein-Barr virus vaccine trial (). This investigational vaccine candidate is being developed in collaboration with Merck and evaluates safety and tolerability in up to 200 h...

 PRESS RELEASE

CPS Announces $418.33 Million Senior Subordinate Asset-Backed Securiti...

CPS Announces $418.33 Million Senior Subordinate Asset-Backed Securitization LAS VEGAS, Nevada, July 28, 2025 (GLOBE NEWSWIRE) -- Consumer Portfolio Services, Inc. (Nasdaq: CPSS) (“CPS” or the “Company”) announced the closing of its third term securitization in 2025 on Monday July 28, 2025. The transaction is CPS's 56th senior subordinate securitization since the beginning of 2011 and the 39th consecutive securitization to receive a triple “A” rating from at least two rating agencies on the senior class of notes. In the transaction, qualified institutional buyers purchased $418.33 millio...

 PRESS RELEASE

OPKO Health to Report Second Quarter 2025 Financial Results on July 31

OPKO Health to Report Second Quarter 2025 Financial Results on July 31 MIAMI, July 24, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and six months ended June 30, 2025 after the close of the U.S. financial markets on Thursday, July 31, 2025. OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on July 31 beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCAST INFORMATION OPKO encourages participants to pre-re...

 PRESS RELEASE

Farmers & Merchants Bancorp (FMCB) Reports Record Second Quarter 2025 ...

Farmers & Merchants Bancorp (FMCB) Reports Record Second Quarter 2025 Earnings Second Quarter 2025 Highlights Net income of $23.1 million, an increase of $1.3 million or 5.9% compared to the second quarter of 2024;Basic earnings per share of $33.06 and diluted earnings per share of $32.94; diluted earnings per share up 12.1% compared to the second quarter of 2024;Diluted earnings per share of $126.87 over the trailing twelve months, up 7.8% compared to $117.73 over the same trailing period a year ago and 15.2% compared to $110.10 for the same period two years ago;Tangible book value per sh...

 PRESS RELEASE

OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Ta...

OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress MIAMI and JERUSALEM, July 08, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (“OPKO”) and Entera Bio Ltd. (NASDAQ: ENTX) (“Entera”) today announced that their abstract “First-in-Class Oral GLP-2 Analog for Treatment of Short Bowel Syndrome” has been selected for a poster presentation at the 47th European Society for Clinical Nutrition & Metabolism (“ESPEN”) Congress, taking place September 13–16, 2025, in Prague, Czech Republic. A...

 PRESS RELEASE

OPKO Health to Participate in the 3rd Annual Piper Sandler Virtual Obe...

OPKO Health to Participate in the 3rd Annual Piper Sandler Virtual Obesity Symposium MIAMI, June 25, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) today announced its participation in the 3rd Annual Piper Sandler Obesity Symposium being held virtually on June 26, 2025. Management will be participating in a fireside discussion moderated by Edward Tentoff, Managing Director, Senior Biotechnology Analyst. Investors can register for the symposium by contacting their Piper Sandler representative. About OPKO Health OPKO is a multinational biopharmaceutical and diagnostics ...

 PRESS RELEASE

OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Gluc...

OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting MIAMI and JERUSALEM, June 25, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX) (“Entera”) today announced that new pharmacologic and pharmacokinetic in vivo data for investigational oral OPK-88006 tablet treatment has been selected for presentation at the ENDO 2025 annual meeting of the Endocrine Society, taking place July 12-15, 2025 in San Francisc...

 PRESS RELEASE

OPKO Health’s ModeX Therapeutics Announces Formation of Scientific Adv...

OPKO Health’s ModeX Therapeutics Announces Formation of Scientific Advisory Board with Leaders at the Forefront of Immunology and Oncology Drug Development Will provide expertise across ModeX’s portfolio of next generation multispecific antibodies for complex diseases involving the immune system, including cancer ModeX’s promising immunology pipeline includes first-in class drugs with two assets in ongoing clinical trials and multiple pre-IND assets to enter clinical trials WESTON, Mass., June 09, 2025 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), to...

Newmark Group Inc: 1 director

A director at Newmark Group Inc sold 10,839,674 shares at 11.580USD and the significance rating of the trade was 92/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...

 PRESS RELEASE

OPKO Health to Participate in Two Upcoming Investor Conferences

OPKO Health to Participate in Two Upcoming Investor Conferences MIAMI, May 15, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in two investor conferences over the coming weeks. H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq, May 20 in New York City. Management will hold one-on-one meetings with investors and will participate in a fireside discussion at 9:00 a.m. Eastern time. Jefferies Global Healthcare Conference, June 3-5 at the Marriott Marquis in New York City. Management will hold one-on-one meet...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch